サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1703444

カルビドパ市場- 世界の市場規模、シェア、動向、機会、予測、販売チャネル別、最終用途別、地域別、競争別、2020-2030F

Carbidopa Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Sales Channel, By End Use, By Region and Competition, 2020-2030F

出版日
ページ情報
英文 185 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

カルビドパ市場- 世界の市場規模、シェア、動向、機会、予測、販売チャネル別、最終用途別、地域別、競争別、2020-2030F
出版日: 2025年04月11日
発行: TechSci Research
ページ情報: 英文 185 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界のカルビドパ市場は、2024年に4億7,512万米ドルと評価され、2030年には6億8,965万米ドルに達し、予測期間中に7.99％の複合年間成長率（CAGR）で拡大すると予測されています。

市場成長の原動力となっているのは、パーキンソン病やその他の神経疾患に関連する治療に対する世界の需要の高まりです。

市場概要
予測期間 2026-2030
市場規模：2024年 4億7,512万米ドル
市場規模：2030年 6億8,965万米ドル
CAGR：2025年～2030年 7.99%
急成長セグメント 間接部門
最大市場 北米

カルビドパは、レボドパの生物学的利用能と治療効果を高めることにより、併用療法（特にレボドパとの併用療法）において重要な役割を果たしています。世界人口の高齢化が進み、パーキンソン病の罹患率が上昇する中、効果的で長期的な治療オプションに対する需要が市場の拡大を加速させています。

競合情勢としては、多国籍製薬企業や地域メーカーが、情勢に応じた治療薬の開発、生産、商業化に積極的に取り組んでいます。研究開発への多額の投資は、特に徐放化技術や放出制御技術による薬剤製剤の最適化に重点を置き、治療成績の向上と副作用の軽減を図っています。戦略的パートナーシップ、合併、ヘルスケア機関との提携は、市場内での技術革新と競争力をさらに高めています。

主な市場促進要因

世界のヘルスケアセクターの拡大

主な市場課題

副作用と安全性への懸念

主要市場動向

併用療法の採用増加

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 COVID-19が世界のカルビドパ市場に与える影響

第5章 世界のカルビドパ市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 販売チャネル別（直接、間接）
    • 用途別（特発性パーキンソン病、脳炎後パーキンソン病、症候性パーキンソン病、その他）
    • 地域別
    • 企業別（2024）
  • 市場マップ

第6章 北米のカルビドパ市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 北米：国別分析
    • 米国
    • メキシコ
    • カナダ

第7章 欧州のカルビドパ市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 欧州：国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第8章 アジア太平洋地域のカルビドパ市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • アジア太平洋地域：国別分析
    • 中国
    • インド
    • 韓国
    • 日本
    • オーストラリア

第9章 南米のカルビドパ市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカのカルビドパ市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 中東・アフリカ：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 合併と買収
  • 製品上市
  • 最近の動向

第13章 世界のカルビドパ市場：SWOT分析

第14章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第15章 競合情勢

  • Smruthi Organics Ltd.
  • Zhejiang Yefeng Pharmaceutical Co., Ltd
  • Divi's Laboratories Limited
  • GreenSyn Life Science
  • Xi'an D-Sung Biotechnology Co., Ltd.
  • Hetero Drugs limited
  • Hangzhou Dingyan Chem Co.,Ltd
  • Zhejiang Yongtai Chiral Pharmaceutical Technology Co., Ltd.
  • Xi'an Yihui Bio-technology Co., Ltd
  • Hanhong Medicine Technology（hubei）co. Ltd

第16章 戦略的提言

第17章 調査会社について・免責事項

目次
Product Code: 28246

Global Carbidopa Market was valued at USD 475.12 million in 2024 and is projected to reach USD 689.65 million by 2030, expanding at a compound annual growth rate (CAGR) of 7.99% during the forecast period. Market growth is being driven by the rising global demand for treatments related to Parkinson's disease and other neurological conditions.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 475.12 Million
Market Size 2030USD 689.65 Million
CAGR 2025-20307.99%
Fastest Growing SegmentIndirect
Largest MarketNorth America

Carbidopa plays a critical role in combination therapies-most notably with levodopa-by increasing levodopa's bioavailability and therapeutic efficacy. As the global population continues to age and the incidence of Parkinson's disease rises, the demand for effective, long-term treatment options is accelerating market expansion.

The competitive landscape includes both multinational pharmaceutical companies and regional manufacturers actively engaged in the development, production, and commercialization of carbidopa-based therapies. Significant investments in research and development are focused on optimizing drug formulations, particularly through extended-release and controlled-release technologies, to enhance treatment outcomes and reduce adverse effects. Strategic partnerships, mergers, and collaborations with healthcare institutions are further driving innovation and competitive positioning within the market.

Key Market Drivers

Expansion of the Global Healthcare Sector

The global growth of the healthcare industry is a major driver for the carbidopa market. Healthcare accounts for a significant share of GDP in developed economies-surpassing 10% in many countries. For instance, in the United States, healthcare expenditure reached USD 4.3 trillion in 2021, equating to USD 12,914 per capita, reflecting a 2.7% year-over-year increase.

Carbidopa is widely used in the treatment of Parkinson's disease and related neurodegenerative conditions. As healthcare infrastructure improves and demand for chronic disease management rises, carbidopa's role as an essential pharmaceutical agent has become increasingly prominent.

Key Market Challenges

Side Effects and Safety Concerns

Despite its clinical value, one of the primary challenges hindering market growth is the range of side effects associated with carbidopa-based therapies. While the combination of carbidopa and levodopa remains a cornerstone in Parkinson's disease treatment, patients often experience side effects such as nausea, dizziness, orthostatic hypotension, and dyskinesia. These can significantly impact quality of life and treatment adherence.

Moreover, long-term use may lead to motor fluctuations, characterized by alternating "on" periods-when the medication is effective-and "off" periods-when symptoms return. These complications can make disease management more difficult and reduce the effectiveness of therapy over time, thereby posing a barrier to wider market adoption.

Key Market Trends

Rising Adoption of Combination Therapies

A notable trend in the carbidopa market is the growing use of combination therapies, particularly with levodopa. The carbidopa-levodopa pairing remains the gold standard for managing motor symptoms of Parkinson's disease. Furthermore, newer formulations such as the levodopa/carbidopa/entacapone triple combination infusion-already launched in select European markets-are gaining traction. Early feedback indicates that patients can transition from traditional jejunal levodopa infusion to this novel therapy with relative ease.

Key Market Players

  • Smruthi Organics Ltd.
  • Zhejiang Yefeng Pharmaceutical Co., Ltd
  • Divi's Laboratories Limited
  • GreenSyn Life Science
  • Xi'an D-Sung Biotechnology Co., Ltd.
  • Hetero Drugs limited
  • Hangzhou Dingyan Chem Co.,Ltd
  • Zhejiang Yongtai Chiral Pharmaceutical Technology Co., Ltd.
  • Xi'an Yihui Bio-technology Co., Ltd
  • Hanhong Medicine Technology (hubei) co. Ltd

Report Scope

In this report, the Global Carbidopa Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Carbidopa Market, By Sales Channel:

  • Direct
  • Indirect

Carbidopa Market, By End Use:

  • Idiopathic Parkinson Disease
  • Postencephalitic Parkinsonism
  • Symptomatic Parkinsonism
  • Others

Carbidopa Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Carbidopa Market.

Available Customizations:

Global Carbidopa Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Carbidopa Market

5. Global Carbidopa Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Sales Channel (Direct, Indirect)
    • 5.2.2. By End Use (Idiopathic Parkinson Disease, Postencephalitic Parkinsonism, Symptomatic Parkinsonism, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Carbidopa Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Sales Channel
    • 6.2.2. By End Use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Carbidopa Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Sales Channel
        • 6.3.1.2.2. By End Use
    • 6.3.2. Mexico Carbidopa Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Sales Channel
        • 6.3.2.2.2. By End Use
    • 6.3.3. Canada Carbidopa Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Sales Channel
        • 6.3.3.2.2. By End Use

7. Europe Carbidopa Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Sales Channel
    • 7.2.2. By End Use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Carbidopa Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Sales Channel
        • 7.3.1.2.2. By End Use
    • 7.3.2. Germany Carbidopa Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Sales Channel
        • 7.3.2.2.2. By End Use
    • 7.3.3. United Kingdom Carbidopa Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Sales Channel
        • 7.3.3.2.2. By End Use
    • 7.3.4. Italy Carbidopa Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Sales Channel
        • 7.3.4.2.2. By End Use
    • 7.3.5. Spain Carbidopa Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Sales Channel
        • 7.3.5.2.2. By End Use

8. Asia Pacific Carbidopa Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Sales Channel
    • 8.2.2. By End Use
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Carbidopa Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Sales Channel
        • 8.3.1.2.2. By End Use
    • 8.3.2. India Carbidopa Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Sales Channel
        • 8.3.2.2.2. By End Use
    • 8.3.3. South Korea Carbidopa Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Sales Channel
        • 8.3.3.2.2. By End Use
    • 8.3.4. Japan Carbidopa Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Sales Channel
        • 8.3.4.2.2. By End Use
    • 8.3.5. Australia Carbidopa Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Sales Channel
        • 8.3.5.2.2. By End Use

9. South America Carbidopa Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Sales Channel
    • 9.2.2. By End Use
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Carbidopa Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Sales Channel
        • 9.3.1.2.2. By End Use
    • 9.3.2. Argentina Carbidopa Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Sales Channel
        • 9.3.2.2.2. By End Use
    • 9.3.3. Colombia Carbidopa Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Sales Channel
        • 9.3.3.2.2. By End Use

10. Middle East and Africa Carbidopa Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Sales Channel
    • 10.2.2. By End Use
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Carbidopa Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Sales Channel
        • 10.3.1.2.2. By End Use
    • 10.3.2. Saudi Arabia Carbidopa Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Sales Channel
        • 10.3.2.2.2. By End Use
    • 10.3.3. UAE Carbidopa Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Sales Channel
        • 10.3.3.2.2. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Carbidopa Market: SWOT Analysis

14. Porters Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Smruthi Organics Ltd.
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. Zhejiang Yefeng Pharmaceutical Co., Ltd
  • 15.3. Divi's Laboratories Limited
  • 15.4. GreenSyn Life Science
  • 15.5. Xi'an D-Sung Biotechnology Co., Ltd.
  • 15.6. Hetero Drugs limited
  • 15.7. Hangzhou Dingyan Chem Co.,Ltd
  • 15.8. Zhejiang Yongtai Chiral Pharmaceutical Technology Co., Ltd.
  • 15.9. Xi'an Yihui Bio-technology Co., Ltd
  • 15.10. Hanhong Medicine Technology (hubei) co. Ltd

16. Strategic Recommendations

17. About Us & Disclaimer